Study of baricitinib on blood clotting in rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests if baricitinib, a medication for rheumatoid arthritis, can improve blood clotting issues that some patients with active RA face. It is for adults whose RA is not well-controlled by standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have rheumatoid arthritis diagnosed by your doctor using standard criteria.
- Your rheumatoid arthritis is active even though you are taking other medications for it.
- You are willing and able to give written permission to be in the study.
- You do not have other autoimmune diseases, diabetes, kidney or liver disease, or a history of blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests whether a JAK inhibitor (baricitinib) can improve how RA-related bone erosion heals. You might be eligible if you have rheumatoid arthritis that is still active despite methotrexate treatment, and you meet the specific safety and medication history rules.
This trial checks how the medication baricitinib affects nerves in people with rheumatoid arthritis. It uses a nerve test to see if the drug causes nerve problems.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This study tests a treatment that stimulates the spleen to help calm symptoms of active rheumatoid arthritis (RA). It’s mainly for people whose RA has not improved enough after several newer arthritis medicines.
This study tests whether the drug baricitinib, given after a mechanical clot-removal procedure, helps improve recovery in people who had a stroke from a large clot in the front of the brain. The drug may reduce inflammation and protect brain tissue.
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.